3,041 Shares in Cencora, Inc. $COR Purchased by Krilogy Financial LLC

Key Points

• Krilogy Financial LLC acquired 3,041 Cencora shares in the third quarter, valued at approximately $913,000. Institutional investors and hedge funds collectively own 97.52% of the company.
• Cencora’s latest quarterly results exceeded expectations, with adjusted earnings of $4.48 per share and revenue of $84.75 billion, up 5.1% year over year.
• Analysts remain broadly positive, with 14 Buy ratings and four Holds, producing a “Moderate Buy” consensus and an average price target of $363.81. The company also pays a quarterly dividend of $0.60 per share.

Krilogy Financial LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,041 shares of the company's stock, valued at approximately $913,000.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Cencora during the second quarter valued at $5,154,136,000. T. Rowe Price Investment Management Inc. grew its position in shares of Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company's stock worth $2,262,956,000 after acquiring an additional 4,123,795 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Cencora by 6.9% in the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company's stock worth $1,300,033,000 after acquiring an additional 267,318 shares during the period. Amundi increased its holdings in shares of Cencora by 43.5% in the 2nd quarter. Amundi now owns 2,229,326 shares of the company's stock worth $630,855,000 after acquiring an additional 676,066 shares during the period. Finally, Carmignac Gestion increased its holdings in shares of Cencora by 58.7% in the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company's stock worth $494,463,000 after acquiring an additional 646,112 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

COR traded down $0.87 on Friday, reaching $340.54. The company had a trading volume of 1,978,868 shares, compared to its average volume of 1,282,490. The company has a market capitalization of $64.99 billion, a P/E ratio of 25.30, a PEG ratio of 1.75 and a beta of 0.58. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. The company has a fifty day moving average of $320.38 and a 200-day moving average of $303.34. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping analysts' consensus estimates of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora's revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $4.00 EPS. As a group, equities research analysts anticipate that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Friday, August 14th. Cencora's dividend payout ratio is 17.83%.

Analyst Ratings Changes

COR has been the topic of several recent research reports. Robert W. Baird boosted their target price on shares of Cencora from $370.00 to $373.00 and gave the company an "outperform" rating in a research note on Monday, October 12th. Citigroup restated a "buy" rating on shares of Cencora in a research report on Thursday, August 6th. Evercore restated an "outperform" rating and issued a $350.00 price target (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Wells Fargo & Company lifted their price target on Cencora from $331.00 to $395.00 and gave the company an "overweight" rating in a report on Tuesday, August 11th. Finally, Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $363.81.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares of the company's stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.38% of the stock is owned by company insiders.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.